Literature DB >> 12465061

Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.

Craig D McColl1, Katrina A Reardon, Mark Shiff, Peter A Kempster.   

Abstract

Thirty-four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disease progresses. Objective measurements of the motor response to levodopa test-doses were made at approximately three yearly intervals. Motor fluctuations developed in 58% of the patient group after a mean treatment period of 35 months. Dyskinesia developed in parallel with fluctuations but appeared on average 7 months before symptomatic wearing-off effects of levodopa doses. The patients with motor fluctuations had significantly better responses to levodopa. By contrast, nonfluctuators were more prone to develop increasing midline motor disability affecting speech, gait and balance. Comparison of test-dose and pretreatment scores suggested that a substantial long-duration response to levodopa remains after many years of treatment, and that lateralized motor deficits show a stronger long duration response than midline ones. Motor fluctuations are a consequence of disease progression but their early development is, on balance, associated with better long-term functional ability because these patients have the greater capacity to respond to pharmacological treatment. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465061     DOI: 10.1002/mds.10244

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Validation of 24-hour ambulatory gait assessment in Parkinson's disease with simultaneous video observation.

Authors:  Steven T Moore; Valentina Dilda; Bandar Hakim; Hamish G Macdougall
Journal:  Biomed Eng Online       Date:  2011-09-21       Impact factor: 2.819

2.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

5.  Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.

Authors:  Jing Han Ng; Angela An Qi See; Zheyu Xu; Nicolas Kon Kam King
Journal:  J Neurol       Date:  2020-05-04       Impact factor: 4.849

6.  Locomotor response to levodopa in fluctuating Parkinson's disease.

Authors:  Steven T Moore; Hamish G MacDougall; Jean-Michel Gracies; William G Ondo
Journal:  Exp Brain Res       Date:  2007-09-08       Impact factor: 1.972

7.  Assessment of Parkinson disease manifestations.

Authors:  Joel S Perlmutter
Journal:  Curr Protoc Neurosci       Date:  2009-10

8.  An objective fluctuation score for Parkinson's disease.

Authors:  Malcolm K Horne; Sarah McGregor; Filip Bergquist
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

9.  A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  Andrew H Evans; Jade Kettlewell; Sarah McGregor; Katya Kotschet; Robert I Griffiths; Malcolm Horne
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

10.  Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  D Tomas; D Stanic; H K Chua; K White; W C Boon; M Horne
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.